{"title":"Prevalence of linezolid resistance in <i>Streptococcus pneumoniae</i> isolates: a systematic review and meta-analysis.","authors":"Mohsen Heidary, Shirin Dashtbin, Arezoo Asadi, Parisa Asadollahi, Ali Khatib, Mohammad Amin Ebrahimi, Zahra Ghanbari, Atieh Darbandi, Roya Ghanavati, Reza Pakzad","doi":"10.2217/fmb-2023-0170","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to understand the current level of linezolid (LNZ) resistance in <i>Streptococcus pneumoniae</i> isolates reported over the past 10 years. <b>Material & methods:</b> An electronic search was conducted for the following keywords: ((<i>Streptococcus pneumoniae</i> [title/abstract]) OR (<i>Pneumococcus</i> [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). <b>Result:</b> Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among <i>S. pneumoniae</i> isolates ranged from 0% to 4.86%. <b>Discussion:</b> Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"449-459"},"PeriodicalIF":2.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2217/fmb-2023-0170","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: This study aimed to understand the current level of linezolid (LNZ) resistance in Streptococcus pneumoniae isolates reported over the past 10 years. Material & methods: An electronic search was conducted for the following keywords: ((Streptococcus pneumoniae [title/abstract]) OR (Pneumococcus [title/abstract]) OR (Pneumococci [title/abstract]) AND (linezolid [title/abstract]) OR (Zyvox [title/abstract])) OR (Zyvoxid [title/abstract])). Result: Out of all the studies, 80 had a cross-sectional design, while 11 followed a cohort approach. The prevalence of LNZ resistance among S. pneumoniae isolates ranged from 0% to 4.86%. Discussion: Urgent, high-powered, randomized, controlled trials with participants from endemic regions are needed to gain a comprehensive understanding of the impact on and significance of LNZ treatment to patients.
期刊介绍:
Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.